(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Stopped Lack of efficacy

Conditions

• Lung Neoplasm
• Carcinoma, Non-Small-Cell Lung
• Respiratory Tract Neoplasms
• Neoplasms
• Neoplasms by Site
• Lung Diseases
• Respiratory Tract Diseases
• Carcinoma, Bronchogenic
• Bronchial Neoplasms
• Adenocarcinoma
• Carcinoma
• Neoplasms by Histologic Type
• Neoplasms, Nerve Tissue
• EGFR C797S
• EGFR C797A
• EGFR L858R
• EGFR Exon 19 Deletion
• EGFR Gene Mutation
• EGF-R Positive Non-Small Cell Lung Cancer
• EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance
• EGFR Activating Mutation
• Thoracic Neoplasms
• Antineoplastic Agents
• Protein Kinase Inhibitors
• EGFR C797G
• EGFR C797X
• Non Small Cell Lung Cancer

Interventions

• DRUG: BLU-701
• DRUG: osimertinib
• DRUG: carboplatin
• DRUG: pemetrexed

Sponsor

Blueprint Medicines Corporation